Apply for Votrient (Pazopanib) Copay Assistance Now

We’ve helped patients save over $65 million on copay assistance. You could be next.

Generic pazopanib can cost over $13,000 per month without assistance. Eligible patients may pay $0 through copay cards, foundation grants, and patient assistance programs. QuickRx coordinates the entire process — at no cost to you.

✓ URAC & ACHC Accredited    ✓ Licensed in All 50 States    ✓ Free Copay Assistance    ✓ Reviewed by a PharmD

Noxafil (posaconazole) copay assistance from QuickRx Specialty Pharmacy

How Much Does Pazopanib (Votrient) Cost in 2026?

Copay (3)

Votrient Cost

Pazopanib is a high-cost oral oncology medication used to treat advanced renal cell carcinoma (kidney cancer) and advanced soft tissue sarcoma. The standard adult dose is 800 mg once daily, taken as four 200 mg tablets on an empty stomach.

Without insurance or copay assistance, the cost of pazopanib can place significant financial strain on patients and families. Pricing varies depending on whether you receive generic pazopanib or brand-name Votrient, your insurance coverage, and your pharmacy.

QuickRx dispenses generic pazopanib, which offers the same active ingredient, strength, dosage form, and FDA-approved indications as brand-name Votrient at a substantially lower price.

Medication Strength AWP per Tablet Approx. Monthly Cost (800 mg/day)
Generic pazopanib HCl (dispensed at QuickRx) 200 mg $112.94 – $160.42 ~$13,550 – $19,250
Brand-name Votrient 200 mg $183.53 ~$22,025

Source: Average Wholesale Price (AWP), Medi-Span/Lexidrug, May 2026. AWP is a reference benchmark; actual patient cost varies by insurance, pharmacy, and assistance programs. Eligible patients may pay $0 through QuickRx-coordinated copay assistance.

At QuickRx, we believe no patient should skip or delay treatment because of cost. Through manufacturer copay cards, independent foundation grants, and patient assistance programs (PAPs), eligible patients may pay $0 for their pazopanib prescription. Call (917) 830-2525 to find out what you may qualify for.

How Pazopanib (Votrient) Copay Assistance Works

Pazopanib copay assistance is a coordinated process that combines several types of financial assistance programs to lower your out-of-pocket cost. QuickRx Patient Navigators handle every step — at no cost to you.

What we coordinate for you:

  • Manufacturer copay cards — For eligible commercially insured patients, often reducing monthly out-of-pocket costs to as low as $0.
  • Independent foundation grants — Critical resources for Medicare, Medicaid, and uninsured patients who do not qualify for manufacturer copay cards.
  • Patient Assistance Programs (PAPs) — Programs that may provide free or significantly discounted pazopanib for qualifying uninsured patients.
  • Benefits investigation & renewal tracking — We monitor copay card expirations and grant renewal windows so your coverage never lapses.

oundation grants, and patient assistance programs (PAPs), eligible patients may pay $0 for their pazopanib prescription. Call (917) 830-2525 to find out what you may qualify for.

Telephone
Step 1: Contact Us

Call (917) 830-2525 or complete the secure form on this page. A QuickRx Patient Navigator will contact you within one business day.

Simple Enrollment Process
Step 2: Simple Enrollment

Your dedicated Patient Navigator reviews your insurance, identifies which copay assistance programs you qualify for, and completes the enrollment paperwork on your behalf — including manufacturer copay cards, foundation grants, and patient assistance applications.

Fast Delivery
Step 3: Coordinated Delivery & Ongoing Monitoring

QuickRx coordinates with your oncologist, arranges nationwide home delivery of your pazopanib, and monitors your case continuously — including refill reminders, copay card renewals, and grant expiration tracking. QuickRx copay assistance services are always free.

Apply for Pazopanib (Votrient) Copay Assistance

Complete the secure form below to begin your pazopanib (Votrient) copay assistance application. A QuickRx Patient Navigator will contact you within one business day to discuss your options and guide you through enrollment.

Your information is protected under HIPAA privacy regulations. QuickRx Specialty Pharmacy is committed to maintaining the confidentiality of your personal health information.

  • This field is for validation purposes and should be left unchanged.
  • PATIENT INFORMATION
  • MM slash DD slash YYYY
  • DOCTOR'S INFORMATION

FAQs

Votrient (Pazopanib) Frequently Asked Questions
How much does generic pazopanib (Votrient) cost without insurance?
Without insurance or assistance, generic pazopanib at an Average Wholesale Price (AWP) of $112.94 to $160.42 per 200 mg tablet (Medi-Span/Lexidrug, May 2026) results in an approximate monthly cost of $13,550 to $19,250 at the standard 800 mg/day dose. Brand-name Votrient is priced higher, at approximately $22,025 per month at AWP. Actual patient cost varies based on insurance, pharmacy, and assistance program eligibility. Eligible patients at QuickRx may pay $0 through copay cards, foundation grants, and patient assistance programs. Call (917) 830-2525 to find out what you may qualify for.
Is there a generic version of Votrient available?
Yes. Generic pazopanib hydrochloride is FDA-approved and widely available in the United States. Generic pazopanib contains the same active ingredient, strength (200 mg tablets), dosage form, and FDA-approved indications as brand-name Votrient, and is the version dispensed at QuickRx. Eligible patients may qualify for copay assistance on generic pazopanib through foundation grants and patient assistance programs. Call (917) 830-2525 to discuss your options.
What is pazopanib (Votrient) copay assistance?
Pazopanib copay assistance is financial help that reduces the out-of-pocket cost of your prescription. It typically combines manufacturer copay cards (for eligible commercially insured patients), independent foundation grants (for Medicare, Medicaid, and uninsured patients), and patient assistance programs (PAPs) that may provide free medication to qualifying uninsured patients. QuickRx Patient Navigators identify which programs you qualify for and handle all enrollment paperwork at no cost to you. Eligible patients may pay $0.
Can Medicare patients get help with pazopanib copay costs?
Yes. Medicare patients are generally not eligible for manufacturer copay cards (this is prohibited by federal law), but they may qualify for independent foundation grants and other forms of financial assistance designed specifically for patients on Medicare and Medicaid. Medicare patients may also qualify for the Medicare Extra Help (Low-Income Subsidy) program, which reduces Part D premiums, deductibles, and copayments. Beginning in 2025, the Inflation Reduction Act capped annual Medicare Part D out-of-pocket costs at $2,000, which significantly benefits patients on high-cost oral oncology medications like pazopanib. QuickRx Patient Navigators help identify and enroll Medicare patients in every program they qualify for.
How long does it take to get pazopanib copay assistance approved?
Most QuickRx patients have their assistance secured and their first pazopanib shipment delivered within 1 to 2 weeks of contacting us. We begin the same day you call. For urgent cases, we work to expedite the process. Our Patient Navigators handle every step — benefits investigation, prior authorization, enrollment paperwork, and coordination with your oncologist’s office — so you can focus on your treatment instead of the paperwork.
What conditions does pazopanib (Votrient) treat?
Pazopanib is FDA-approved to treat two types of cancer in adults: advanced renal cell carcinoma (advanced kidney cancer) and advanced soft tissue sarcoma in patients who have received prior chemotherapy. The efficacy of pazopanib for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors (GIST) has not been demonstrated. Pazopanib is also studied and used off-label in certain cases of unresectable or metastatic chondrosarcoma, progressive desmoid tumors, and advanced differentiated thyroid cancer.
How does pazopanib work to treat cancer?
Pazopanib is an oral tyrosine kinase inhibitor (TKI). It works by blocking several receptors involved in tumor growth and the formation of new blood vessels (a process called angiogenesis), including vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and stem cell factor receptor (cKIT). By blocking these signals, pazopanib slows the growth and spread of cancer cells and cuts off the blood supply tumors need to grow.
What is the standard dose of pazopanib?
The standard adult dose of pazopanib for both advanced renal cell carcinoma and advanced soft tissue sarcoma is 800 mg once daily, taken as four 200 mg tablets. Pazopanib must be taken on an empty stomach — either 1 hour before or 2 hours after a meal — because taking it with food roughly doubles its blood levels and can increase side effects. Tablets must be swallowed whole and should not be crushed. Your oncologist may adjust your dose based on liver function, kidney function, side effects, or other medications you take.
What are the most common side effects of pazopanib?
The most common side effects of pazopanib (occurring in more than 20% of patients) include diarrhea, high blood pressure (hypertension), hair color changes (often lightening to gray), nausea and vomiting, fatigue, decreased appetite, elevated liver enzymes (AST and ALT), weight loss, and tumor pain. Many patients also experience headache, taste changes, and abdominal pain. Tell your oncologist about any side effects you experience — many can be managed with supportive care or dose adjustments. This is not a complete list. Review the full prescribing information with your healthcare provider.
What is the black box warning on pazopanib?
Pazopanib carries an FDA boxed warning for hepatotoxicity (severe and fatal liver injury). Liver enzyme elevations (ALT and AST) and bilirubin elevations have been reported in clinical trials, and rare deaths from hepatic failure have occurred. Most transaminase elevations occur within the first 18 weeks of treatment. Your oncologist will monitor your liver function with blood tests at baseline; at weeks 3, 5, 7, and 9; at months 3 and 4; and periodically thereafter. Call your doctor right away if you develop: yellow skin or eyes, dark urine, light-colored stools, severe stomach pain, unusual fatigue, or loss of appetite.
Can I drink grapefruit juice while taking pazopanib?
No. Avoid grapefruit and grapefruit juice while taking pazopanib. Grapefruit inhibits the CYP3A4 liver enzyme that metabolizes pazopanib, which can significantly increase pazopanib blood levels and the risk of serious side effects. This applies to fresh grapefruit, grapefruit juice, and any product containing grapefruit. Discuss any other dietary or supplement questions with your oncologist or pharmacist.
Can I take antacids or acid reducers with pazopanib?
Pazopanib absorption is significantly reduced by proton pump inhibitors (PPIs) such as omeprazole or esomeprazole, and by H2 receptor antagonists such as famotidine, so these should generally be avoided. If you need acid-reducing medication, short-acting antacids taken several hours apart from pazopanib are preferred. Always talk to your oncologist or pharmacist before starting any new medication — including over-the-counter products — while taking pazopanib.
What should I do if I miss a dose of pazopanib?
If you miss a dose of pazopanib, do not take it if there are less than 12 hours until your next scheduled dose. Skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are unsure what to do, contact your oncologist, your QuickRx Patient Navigator, or your pharmacist for guidance.
Do I need to monitor my blood pressure while taking pazopanib?
Yes. Approximately 40% of patients taking pazopanib develop high blood pressure, often within the first 18 weeks of treatment. Your oncologist will check your blood pressure before you start pazopanib and recommend regular monitoring throughout treatment, often including home blood pressure checks during the first cycle, after any dose increases, and every 2 to 3 weeks thereafter. If hypertension develops, your oncologist may prescribe blood pressure medication and/or adjust your pazopanib dose.
Can I have surgery while taking pazopanib?
Pazopanib can impair wound healing. Pazopanib should be withheld for at least 1 week before any elective surgery and should not be resumed for at least 2 weeks after major surgery and until adequate wound healing has occurred. Tell every healthcare provider you see — including dentists and surgeons — that you take pazopanib. Never stop or adjust your pazopanib dose without consulting your oncologist first.
How long will I need to take pazopanib?
Pazopanib is typically continued until your disease progresses or until you experience side effects that require permanent discontinuation. The length of treatment varies significantly from patient to patient based on individual response. Your oncologist will reassess your treatment at regular intervals based on imaging, lab results, and how you are tolerating the medication. Never stop, start, or change your pazopanib dose without your oncologist’s guidance. If cost is a barrier to staying on treatment, call QuickRx at (917) 830-2525 immediately — we can often secure copay assistance the same day you contact us.
Is pazopanib safe during pregnancy or breastfeeding?
No. Pazopanib can cause fetal harm based on animal studies and its mechanism of action. Patients who could become pregnant should use effective contraception during pazopanib treatment and for at least 2 weeks after the last dose. Male patients (including those who have had a vasectomy) with partners who could become pregnant should use condoms during treatment and for at least 2 weeks after the last dose. Breastfeeding should be discontinued during pazopanib treatment and for 2 weeks after the last dose due to the potential for serious adverse reactions in breastfed infants.
Medical Disclaimer
The information on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider regarding your specific medical condition, treatment options, and prescription medications. Pazopanib (Votrient) is a prescription medication and may not be appropriate for all patients. Pricing data on this page reflects Average Wholesale Price (AWP) as published in Medi-Span/Lexidrug and is provided as a reference benchmark only; actual patient cost varies by insurance, pharmacy, and assistance program eligibility. QuickRx Specialty Pharmacy is a URAC- and ACHC-accredited pharmacy licensed to dispense in all 50 states.
References
1. Votrient (pazopanib) Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2024. FDA-Approved Labeling
2. Pazopanib (Lexi-Drugs). UpToDate Lexidrug™. Wolters Kluwer Clinical Drug Information. Last Updated May 7, 2026.
3. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731. PubMed: 23964934
4. Van Der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886. PubMed: 22595799
5. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229-4361. PubMed: 36017568
6. National Cancer Institute — Renal Cell Cancer Treatment
7. National Cancer Institute — Soft Tissue Sarcoma Treatment
About the Authors
Authored by: Paola Larrabure, Pharma Content Manager, QuickRx Specialty Pharmacy.
Clinically reviewed by: Julia Kravtsova, PharmD, Head Patient Navigator, QuickRx Specialty Pharmacy.
Last reviewed: May 12, 2026.

Start Your Pazopanib Copay Assistance Today

You don’t have to navigate copay assistance, foundation grants, and prior authorizations alone. QuickRx Patient Navigators handle every step at no cost to you — so you can focus on your treatment, not the paperwork.

Eligible patients may pay $0 for their pazopanib prescription.

Call (917) 830-2525 to speak with a QuickRx Patient Navigator now, or complete the secure form above. We’ll contact you within one business day.

Get Started